<DOC>
	<DOCNO>NCT02470039</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare NNC0123-0000-0338 ( insulin-338 ) tablet formulation insulin glargine combination metformin without DPP-4 inhibitor subject type 2 diabetes currently treat oral antidiabetic therapy .</brief_summary>
	<brief_title>Trial Compare NNC0123-0000-0338 Tablet Formulation Insulin Glargine Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Age 1870 year ( inclusive ) time sign informed consent Body mass index 25.040.0 kg/m^2 ( inclusive ) Subject diagnose ( clinically ) type 2 diabetes mellitus least 180 day prior day screen Insulin na√Øve subject ; however , short term insulin treatment maximum 14 day prior day screen allow , prior insulin treatment gestational diabetes Known suspected hypersensitivity trial product related product Any disorder investigator 's opinion might jeopardise subject 's safety compliance protocol Presence clinically significant gastrointestinal disorder potentially affect absorption drug and/or nutrient , judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>